Kiora Pharmaceuticals Inc (KPRX) FinancialsKPRXKiora Pharmaceuticals Inc

Evaluating the bottom line, Kiora Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -56.36%, provide a clear picture of how effectively KPRX converts its operational activities into shareholder value.

In the context of the broader market, KPRX competes directly with industry leaders such as CNSP and LEXX. With a market capitalization of $6.23M, it holds a significant position in the sector. When comparing efficiency, KPRX's gross margin of N/A stands against CNSP's N/A and LEXX's 100.00%. Such benchmarking helps identify whether Kiora Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Kiora Pharmaceuticals has shown significant financial struggles, with a net income loss of -$2,417,984 in Q1 2026 and a gross margin of 0% in recent quarters, indicating no revenue generation. The company has also reported a consistent decline in common stock equity, dropping from $25,759,772 in Q4 2024 to $16,856,685 in Q2 2026.